Lite Strategy, Inc. (LITS) Research

Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.

Market snapshot

Symbol
LITS
Price
$0.83
Day change
-9.94%
Market cap
$28.2M
P/E ratio
-0.09x
52-week range
0.69-9
Sector
Financial Services
Industry
Asset Management - Cryptocurrency
Next earnings
in 3 months

Peer companies

  • Adicet Bio, Inc. (ACET)
  • Acrivon Therapeutics, Inc. Common Stock (ACRV)
  • Werewolf Therapeutics, Inc. (HOWL)
  • Immunic, Inc. (IMUX)
  • IO Biotech, Inc. (IOBT)
  • Nutriband Inc. (NTRB)
  • PMV Pharmaceuticals, Inc. (PMVP)
  • Relmada Therapeutics, Inc. (RLMD)

Recent insider activity

  • File Justin J. — A-Award (455000 shares) on 2026-02-12
  • Schornstein Alexander — S-Sale (690611 shares) on 2025-12-18
  • Flynn James P — P-Purchase (70000 shares) on 2025-12-19
  • File Justin J. — A-Award (180000 shares) on 2025-11-14
  • Flynn James P — P-Purchase (12100 shares) on 2025-11-19

Open Lite Strategy, Inc. (LITS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.